Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use

Multiple sclerosis (MS) is a chronic progressive neurodegenerative demyelinating disease affecting the central nervous system. Glatiramer acetate (GA; Copaxone®) was the first disease-modifying treatment (DMT) for MS successfully tested in humans (1977) and was approved by the US Food and Drug Admin...

Descripción completa

Detalles Bibliográficos
Autor principal: Wynn, Daniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350531/
https://www.ncbi.nlm.nih.gov/pubmed/30775037
http://dx.doi.org/10.1155/2019/7151685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350531/
https://www.ncbi.nlm.nih.gov/pubmed/30775037
http://dx.doi.org/10.1155/2019/7151685

Ejemplares similares